Diazoxide is an oral hyperglycemic medication. Diazoxide has been proven effective for treating hypoglycemia in infants and children with some types of persistent hyperinsulinemic hypoglycemia. The mechanism of action results in decreased insulin secretion. One of the causes of hypoglycemia in infants of diabetic mothers occurs due to a transient hyperinsulinemic state postnatally. The investigators have clinical experience and success using diazoxide in their unit for patients with hypoglycemia not adequately managed with intravenous (iv) dextrose and enteral supplementation. In this randomized controlled study the investigators expect that by using diazoxide as the initial treatment for infants of diabetic mothers with asymptomatic hypoglycemia (blood glucose of 2.5 to 2.0mmol/L), the investigators will be able to decrease the number of infants requiring an intravenous by at least thirty percent.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
100
Royal University Hospital
Saskatoon, Saskatchewan, Canada
Blood glucose measurement less than 2.0mmol/L
Time frame: 14 days
Number of infants with significantly low blood glucose measurements (<1.5mmol/L).
Time frame: 14 days
Length of stay for infants in hospital
Time frame: 14 days
Need for intravenous dextrose infusion to maintain blood glucose above 2.0mmol/L
Time frame: 14 days
Admission to neonatal intensive care unit (NICU)
Time frame: 14 days
Thrombocytopenia and/or Leukopenia
Time frame: 14 days
Electrolyte imbalance requiring clinical intervention (intravenous or oral)
Time frame: 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.